Inhibition of the PD-1/PD-L1 immune checkpoint pathway using mAbs against either PD-L1 or PD-1 has proven to be highly successful in treating a wide range of cancers (1); however, there remain some significant limitations including poor tumor penetration (9), off target toxicity (10), and declining patient response over time (11). Here, PDCD1 is linked to neoplasm.